Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;191(7):1858-1869.
doi: 10.1002/ajmg.a.63216. Epub 2023 Apr 20.

Long-term effectiveness of enzyme replacement therapy in Fabry disease with the p.Arg227Ter variant: Fabry disease in Ostrobothnia (FAST) study

Päivi Pietilä-Effati  1 , Jukka T Saarinen  2 , Eliisa Löyttyniemi  3 , Maria Saarenhovi  4 , Reijo Autio  5 , Ilkka Kantola  6
Affiliations

Long-term effectiveness of enzyme replacement therapy in Fabry disease with the p.Arg227Ter variant: Fabry disease in Ostrobothnia (FAST) study

Päivi Pietilä-Effati et al. Am J Med Genet A. 2023 Jul.

Abstract

Fabry disease (FD) is an X chromosome-linked, life-threatening lysosomal disease caused by one of more than 1000 currently known variants in the α-galactosidase A (GLA) gene. The follow-up part of the Fabry Disease in Ostrobothnia (FAST) study reports the long-term effect of enzyme replacement therapy (ERT) on a prospectively collected cohort of 12 patients, 4 males and 8 females, mean age 46 years (SD 16), with the classical variant c.679C > T p.Arg227Ter, which is one of the most common FD variants worldwide. In the natural history period of the FAST study, half of the patients in both sexes had at least one major event, of which 80% were of cardiac origin. During 5 years of ERT, four patients had a total of six major clinical events consisting of one silent ischemic stroke, three ventricular tachycardias and two increased left ventricular mass indexes. In addition, four patients developed minor cardiac events, four patients minor renal events, and one patient a minor neurological event. ERTs may delay but not prevent the progression of the disease in most patients with the variant Arg227Ter. This variant might be suitable for investigating the efficacy of second-generation ERTs compared to the currently used ERTs regardless of sex.

Keywords: Fabry disease; efficacy; enzyme replacement therapy; follow-up study; sex; variant.

PubMed Disclaimer

References

REFERENCES

    1. Al Rifai, M., Yao, J., Guo, X., Post, W. S., Malik, S., Blumenthal, R. S., Ballantyne, C. M., Budoff, M., Taylor, K. D., Lin, H. J., Rich, S. S., Hajek, C., Greenland, P., Rotter, J. I., & Virani, S. S. (2022). Association of polygenic risk scores with incident atherosclerotic cardiovascular disease events among individuals with coronary artery calcium score of zero: The multi-ethnic study of atherosclerosis. Progress in Cardiovascular Diseases, 74, 19-27. https://doi.org/10.1016/j.pcad.2022.08.003
    1. Arends, M., Biegstraaten, M., Hughes, D. A., Mehta, A., Elliott, P. M., Oder, D., Watkinson, O. T., Vaz, F. M., van Kuilenburg, A. B. P., Wanner, C., & Hollak, C. E. M. (2017). Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors. PLoS One, 12(8), e0182379. https://doi.org/10.1371/journal.pone.0182379
    1. Arends, M., Biegstraaten, M., Wanner, C., Sirrs, S., Mehta, A., Elliott, P. M., Oder, D., Watkinson, O. T., Bichet, D. G., Khan, A., Iwanochko, M., Vaz, F. M., van Kuilenburg, A. B. P., West, M. L., Hughes, D. A., & Hollak, C. E. M. (2018). Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: An international cohort study. Journal of Medical Genetics, 55(5), 351-358. https://doi.org/10.1136/jmedgenet-2017-104863
    1. Arends, M., Wanner, C., Hughes, D., Mehta, A., Oder, D., Watkinson, O. T., Elliott, P. M., Linthorst, G. E., Wijburg, F. A., Biegstraaten, M., & Hollak, C. E. (2017). Characterization of classical and nonclassical Fabry disease: A multicenter study. Journal of the American Society of Nephrology, 28(5), 1631-1641. https://doi.org/10.1681/ASN.2016090964
    1. Arends, M., Wijburg, F. A., Wanner, C., Vaz, F. M., van Kuilenburg, A. B. P., Hughes, D. A., Biegstraaten, M., Mehta, A., Hollak, C. E. M., & Langeveld, M. (2017). Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Molecular Genetics and Metabolism, 121(2), 157-161. https://doi.org/10.1016/j.ymgme.2017.05.001

Publication types

Substances

LinkOut - more resources